HRP20170462T1 - Protutijela za epidermalni receptor 3 faktora rasta (her3) - Google Patents

Protutijela za epidermalni receptor 3 faktora rasta (her3) Download PDF

Info

Publication number
HRP20170462T1
HRP20170462T1 HRP20170462TT HRP20170462T HRP20170462T1 HR P20170462 T1 HRP20170462 T1 HR P20170462T1 HR P20170462T T HRP20170462T T HR P20170462TT HR P20170462 T HRP20170462 T HR P20170462T HR P20170462 T1 HRP20170462 T1 HR P20170462T1
Authority
HR
Croatia
Prior art keywords
seq
her3
antibody
cdr2
cdr3
Prior art date
Application number
HRP20170462TT
Other languages
English (en)
Inventor
Winfried Elis
Seth Ettenberg
Andrew Paul Garner
Nicole Haubst
Christian Carsten Silvester Kunz
Elizabeth Anne Reisinger Sprague
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44630597&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20170462(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of HRP20170462T1 publication Critical patent/HRP20170462T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3023—Lung
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3038—Kidney, bladder
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3053—Skin, nerves, brain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)

Claims (36)

1. Izolirano protutijelo ili njegov fragment koji prepoznaje konformacijski epitop za HER3-receptor, naznačen/o time, da konformacijski epitop obuhvaća aminokiselinske ostatke 265-277, 315 unutar domene 2 i aminokiselinske ostatke 571, 582-584, 596-597, 600-602, 609-615 unutar domene 4 od HER3-receptora od SEQ ID NO:1, te pritom protutijelo ili njegov fragment blokira obje signalne transdukcije od HER3, onu koja je ovisna o ligandu i onu koja nije ovisna o ligandu.
2. Izolirano protutijelo ili njegov fragment prema zahtjevu 1, naznačen/o time, da izolirano protutijelo ili njegov fragment: (a) se veže na neaktivno stanje od HER3-receptora; ili (b) stabilizira HER3-receptor u neaktivnom stanju.
3. Izolirano protutijelo ili njegov fragment prema zahtjevu 2, naznačen/o time, da vezanje protutijela stabilizira HER3-receptor u neaktivnom stanju, te se pritom HER3-ligand može istovremeno vezati na mjesto vezanja za ligand na HER3-receptoru.
4. Izolirano protutijelo ili njegov fragment prema zahtjevu 3, naznačen/o time, da HER3-ligand koji se veže na mjesto vezanja za ligand, ne uspijeva: (a) inducirati konformacijsku promjenu u HER3-receptoru na aktivno stanje; ili (b) aktivirati signalnu transdukciju.
5. Izolirano protutijelo ili njegov fragment prema zahtjevu 1, naznačen/o time, da se protutijelo ili njegov fragment veže na neaktivni HER3-receptor, te se pritom: (a) VH od protutijela ili njegovog fragmenta veže na barem jedan od sljedećih HER3-ostataka: Asn266, Lys267, Leu268, Thr269, Gln271, Glu273, Pro274, Asn275, Pro276, His277, Asn315, Asp571, Pro583, His584, Ala596, Lys597; ili (b) VL od protutijela ili njegovog fragmenta veže na barem jedan od sljedećih HER3-ostataka: Tyr265, Lys267, Leu268, Phe270, Gly582, Pro583, Lys597, Ile600, Lys602, Glu609, Arg611, Pro612, Cys613, His614, Glu615.
6. Izolirano protutijelo ili njegov fragment prema zahtjevu 1, naznačen/o time, da izolirano protutijelo ili njegov fragment prepoznaje konformacijski epitop od prvog HER3-receptora, te pritom: (a) vezanje protutijela ili njegovog fragmenta na prvi HER3-receptor u odsutnosti liganda HER3-receptora, smanjuje tvorbu neovisnu o ligandu, proteinskog kompleksa od prvog HER3-receptora i drugog HER3-receptora, u stanici koja izražava prvi HER3-receptor i drugi HER3-receptor; ili (b) vezanje protutijela ili njegovog fragmenta na prvi HER3-receptor u prisutnosti HER3-liganda, smanjuje tvorbu ovisnu o ligandu, proteinskog kompleksa od prvog HER3-receptora i drugog HER3-receptora, u stanici koja izražava prvi HER3-receptor i drugi HER3-receptor.
7. Izolirano protutijelo ili njegov fragment prema zahtjevu 6, naznačen/o time, da: (a) u odsutnosti liganda HER3-receptora, protutijelo ili njegov fragment stabilizira prvi HER3-receptor u neaktivnom stanju tako, da prvi HER3-receptor ne uspijeva dimerizirati s drugim HER3-receptorom za tvorbu proteinskog kompleksa od prvog HER3-receptora i drugog HER3-receptora; ili (b) u prisutnosti prvog HER3-liganda, protutijelo ili njegov fragment stabilizira prvi HER3-receptor u neaktivnom stanju tako, da HER3-receptor ne uspijeva dimerizirati s drugim HER3-receptorom za tvorbu proteinskog kompleksa od prvog HER3-receptora i drugog HER3-receptora.
8. Izolirano protutijelo ili njegov fragment prema zahtjevu 7, naznačen/o time, da neuspjeh tvorbe proteinskog kompleksa od prvog HER3-receptora i drugog HER3-receptora, sprečava aktiviranje signalne transdukcije.
9. Izolirano protutijelo ili njegov fragment prema zahtjevu 1, naznačen/o time, da: (a) vezanje protutijela ili njegovog fragmenta na HER3-receptor u odsutnosti HER3-liganda, smanjuje tvorbu neovisnu o ligandu, proteinskog kompleksa HER2-HER3, u stanici koja izražava HER2 i HER3; ili (b) vezanje protutijela ili njegovog fragmenta na HER3-receptor u prisutnosti HER3-liganda, smanjuje tvorbu ovisnu o ligandu, proteinskog kompleksa HER2-HER3, u stanici koja izražava HER2 i HER3.
10. Izolirano protutijelo ili njegov fragment prema zahtjevu 9, naznačen/o time, da: (a) u odsutnosti liganda, protutijelo ili njegov fragment stabilizira HER3-receptor u neaktivnom stanju tako, da HER3-receptor ne uspijeva dimerizirati s HER2-receptorom u svrhu tvorbe proteinskog kompleksa HER2-HER3; ili (b) u prisutnosti HER3-liganda, protutijelo ili njegov fragment stabilizira HER3-receptor u neaktivnom stanju tako, da HER3-receptor ne uspijeva dimerizirati s HER2-receptorom u svrhu tvorbe proteinskog kompleksa HER2-HER3.
11. Izolirano protutijelo ili njegov fragment prema zahtjevu 10, naznačen/o time, da neuspjeh tvorbe proteinskog kompleksa HER2-HER3, sprečava aktiviranje signalne transdukcije.
12. Izolirano protutijelo ili njegov fragment prema zahtjevu 1, naznačen/o time, da je protutijelo odabrano iz skupine koju čine: monoklonalno protutijelo, poliklonalno protutijelo, kimerno protutijelo, humanizirano protutijelo i sintetičko protutijelo.
13. Izolirano protutijelo ili njegov fragment prema zahtjevu 3, 6 ili 9, naznačen/o time, da je HER3-ligand odabran iz skupine koju čine neuregulin 1 (NRG), neuregulin 2, betacelulin, epidermalni faktor rasta koji veže heparin, i epiregulin.
14. Izolirano protutijelo ili njegov fragment prema zahtjevu 1, naznačen/o time, da protutijelo ili njegov fragment inhibira fosforilaciju od HER3 kao što se utvrđuje putem sljedećeg: 1. fosforilacijska analiza neovisna o HER3-ligandu; ili 2. fosforilacijska analiza ovisna o HER3-ligandu.
15. Izolirano protutijelo ili njegov fragment prema zahtjevu 14, naznačen/o time, da: a) fosforilacijska analiza neovisna o HER3-ligandu, upotrebljava HER2-amplificirane stanice, gdje HER2-amplificirane stanice su SK-Br-3-stanice; i b) fosforilacijska analiza ovisna o HER3-ligandu, upotrebljava stimulirane MCF7-stanice u prisutnosti neuregulina (NRG).
16. Izolirano protutijelo ili njegov fragment prema zahtjevu 1, naznačen/o time, da se protutijelo ili njegov fragment unakrsno natječe s ili se veže na isti konformacijski epitop kao i sljedeća protutijela: MOR9823; MOR9824; MOR9825; MOR9974; MOR10452; MOR10701; MOR10702; MOR10703; MOR10703 N52S; MOR10703 N52G; MOR10703 N52S_S52aN; MOR10703 A50V_N52S; MOR10703 A50V_N52G; MOR10703 S52aT;MOR10701 R55S; MOR1070155G; MOR10701 R55K; MOR10701 delS56; MOR12609 ili MOR12610, kao što su definirana u Tablici 1.
17. Izolirano protutijelo ili njegov fragment prema bilo kojem od prethodnih zahtjeva, naznačen/o time, da je protutijelo odabrano iz skupine koju čine: monoklonalno protutijelo, kimerno protutijelo, protutijelo jednostrukog lanca, Fab, i scFv.
18. Izolirano protutijelo ili njegov fragment prema bilo kojem od prethodnih zahtjeva, naznačen/o time, da protutijelo je ljudsko protutijelo.
19. Izolirano protutijelo ili njegov fragment prema bilo kojem od prethodnih zahtjeva, naznačen/o time, da protutijelo obuhvaća ljudsko konstantno područje jakog lanca i ljudsko konstantno područje slabog lanca.
20. Izolirano protutijelo ili njegov fragment prema bilo kojem od prethodnih zahtjeva, naznačen/o time, da se protutijelo ili njegov fragment veže i na ljudski HER3 i na HER3 od makaki dugorepih majmuna.
21. Izolirano protutijelo ili njegov fragment prema bilo kojem od prethodnih zahtjeva, naznačen/o time, da protutijelo ili njegov fragment je IgG-izotip.
22. Izolirano protutijelo ili njegov fragment prema bilo kojem od prethodnih zahtjeva, naznačen/o time, da protutijelo obuhvaća okvir u kojem se aminokiseline supstituiraju u okviru protutijela od odgovarajućih humanih VH ili VL sekvenci od populacije stanica.
23. Izolirano protutijelo ili njegov fragment prema zahtjevu 1, naznačen/o time, da obuhvaća 6 CDR-ova od bilo kojeg od sljedećih protutijela, prema izračunu putem sustava Kabat ili Chothia: MOR9823; MOR9824; MOR9825; MOR9974; MOR10452; MOR10701; MOR10702; MOR10703; MOR10703 N52S; MOR10703 N52G; MOR10703 N52S_S52aN; MOR10703 A50V_N52S; MOR10703 A50V_N52G; MOR10703 S52aT; MOR10701 R55S; MOR10701R55G; MOR10701 R55K; MOR10701 delS56; MOR12609 ili MOR12610, kao što su definirana u Tablici 1.
24. Izolirano protutijelo ili njegov fragment prema zahtjevu 1, naznačen/o time, da obuhvaća sljedeće: a) VH koji obuhvaća SEQ ID NO:15 i VL koji obuhvaća SEQ ID NO:14, ili aminokiselinsku sekvencu s 97-99% identiteta od navedenih; ili b) VH koji obuhvaća SEQ ID NO:33 i VL koji obuhvaća SEQ ID NO:32, ili aminokiselinsku sekvencu s 97-99% identiteta od navedenih; ili c) VH koji obuhvaća SEQ ID NO:51 i VL koji obuhvaća SEQ ID NO:50, ili aminokiselinsku sekvencu s 97-99% identiteta od navedenih; ili d) VH koji obuhvaća SEQ ID NO:69 i VL koji obuhvaća SEQ ID NO:68, ili aminokiselinsku sekvencu s 97-99% identiteta od navedenih; ili e) VH koji obuhvaća SEQ ID NO:87 i VL koji obuhvaća SEQ ID NO:86, ili aminokiselinsku sekvencu s 97-99% identiteta od navedenih; ili f) VH koji obuhvaća SEQ ID NO:105 i VL koji obuhvaća SEQ ID NO:104, ili aminokiselinsku sekvencu s 97-99% identiteta od navedenih; ili g) VH koji obuhvaća SEQ ID NO:123 i VL koji obuhvaća SEQ ID NO:122, ili aminokiselinsku sekvencu s 97-99% identiteta od navedenih; ili h) VH koji obuhvaća SEQ ID NO:141 i VL koji obuhvaća SEQ ID NO:140, ili aminokiselinsku sekvencu s 97-99% identiteta od navedenih; ili i) VH koji obuhvaća SEQ ID NO:159 i VL koji obuhvaća SEQ ID NO:158, ili aminokiselinsku sekvencu s 97-99% identiteta od navedenih; ili j) VH koji obuhvaća SEQ ID NO:177 i VL koji obuhvaća SEQ ID NO:176, ili aminokiselinsku sekvencu s 97-99% identiteta od navedenih; ili k) VH koji obuhvaća SEQ ID NO:195 i VL koji obuhvaća SEQ ID NO:194, ili aminokiselinsku sekvencu s 97-99% identiteta od navedenih; ili l) VH koji obuhvaća SEQ ID NO:213 i VL koji obuhvaća SEQ ID NO:212, ili aminokiselinsku sekvencu s 97-99% identiteta od navedenih; ili m) VH koji obuhvaća SEQ ID NO:231 i VL koji obuhvaća SEQ ID NO:230, ili aminokiselinsku sekvencu s 97-99% identiteta od navedenih; ili n) VH koji obuhvaća SEQ ID NO:249 i VL koji obuhvaća SEQ ID NO:248, ili aminokiselinsku sekvencu s 97-99% identiteta od navedenih; ili o) VH koji obuhvaća SEQ ID NO:267 i VL koji obuhvaća SEQ ID NO:266, ili aminokiselinsku sekvencu s 97-99% identiteta od navedenih; ili p) VH koji obuhvaća SEQ ID NO:285 i VL koji obuhvaća SEQ ID NO:284, ili aminokiselinsku sekvencu s 97-99% identiteta od navedenih; ili q) VH koji obuhvaća SEQ ID NO:303 i VL koji obuhvaća SEQ ID NO:302, ili aminokiselinsku sekvencu s 97-99% identiteta od navedenih; ili r) VH koji obuhvaća SEQ ID NO:321 i VL koji obuhvaća SEQ ID NO:320, ili aminokiselinsku sekvencu s 97-99% identiteta od navedenih; ili s) VH koji obuhvaća SEQ ID NO:339 i VL koji obuhvaća SEQ ID NO:338, ili aminokiselinsku sekvencu s 97-99% identiteta od navedenih; ili t) VH koji obuhvaća SEQ ID NO:357 i VL koji obuhvaća SEQ ID NO:356, ili aminokiselinsku sekvencu s 97-99% identiteta od navedenih; ili u) VH koji obuhvaća SEQ ID NO:375 i VL koji obuhvaća SEQ ID NO:374, ili aminokiselinsku sekvencu s 97-99% identiteta od navedenih.
25. Izolirano protutijelo ili njegov fragment prema zahtjevu 1, naznačen/o time, da obuhvaća varijabilnu sekvencu jakog lanca koja ima SEQ ID NO:493 i/ili varijabilnu sekvencu slabog lanca koja ima SEQ ID NO:494.
26. Izolirano protutijelo ili njegov fragment prema zahtjevu 1, naznačen/o time, da obuhvaća sljedeće: a) varijabilno područje jakog lanca CDR1 od SEQ ID NO:2; CDR2 od SEQ ID NO:3; CDR3 od SEQ ID NO:4; varijabilno područje slabog lanca CDR1 od SEQ ID NO:5; CDR2 od SEQ ID NO:6, i CDR3 od SEQ ID NO:7; ili b) varijabilno područje jakog lanca CDR1 od SEQ ID NO:20; CDR2 od SEQ ID NO:21; CDR3 od SEQ ID NO:22; varijabilno područje slabog lanca CDR1 od SEQ ID NO:23; CDR2 od SEQ ID NO:24, i CDR3 od SEQ ID NO:25; ili c) varijabilno područje jakog lanca CDR1 od SEQ ID NO:38; CDR2 od SEQ ID NO:39; CDR3 od SEQ ID NO:40; varijabilno područje slabog lanca CDR1 od SEQ ID NO:41; CDR2 od SEQ ID NO:42, i CDR3 od SEQ ID NO:43; ili d) varijabilno područje jakog lanca CDR1 od SEQ ID NO:56; CDR2 od SEQ ID NO:57; CDR3 od SEQ ID NO:58; varijabilno područje slabog lanca CDR1 od SEQ ID NO:59; CDR2 od SEQ ID NO:60, i CDR3 od SEQ ID NO:61; ili e) varijabilno područje jakog lanca CDR1 od SEQ ID NO:74; CDR2 od SEQ ID NO:75; CDR3 od SEQ ID NO:76; varijabilno područje slabog lanca CDR1 od SEQ ID NO:77; CDR2 od SEQ ID NO:78, i CDR3 od SEQ ID NO:79; ili f) varijabilno područje jakog lanca CDR1 od SEQ ID NO:92; CDR2 od SEQ ID NO:93; CDR3 od SEQ ID NO:94; varijabilno područje slabog lanca CDR1 od SEQ ID NO:95; CDR2 od SEQ ID NO:96, i CDR3 od SEQ ID NO:97; ili g) varijabilno područje jakog lanca CDR1 od SEQ ID NO:110; CDR2 od SEQ ID NO:111; CDR3 od SEQ ID NO:112; varijabilno područje slabog lanca CDR1 od SEQ ID NO:113; CDR2 od SEQ ID NO:114, i CDR3 od SEQ ID NO:115; ili h) varijabilno područje jakog lanca CDR1 od SEQ ID NO:128; CDR2 od SEQ ID NO:129; CDR3 od SEQ ID NO:130; varijabilno područje slabog lanca CDR1 od SEQ ID NO:131; CDR2 od SEQ ID NO:132, i CDR3 od SEQ ID NO:133; ili i) varijabilno područje jakog lanca CDR1 od SEQ ID NO:146; CDR2 od SEQ ID NO:147; CDR3 od SEQ ID NO:148; varijabilno područje slabog lanca CDR1 od SEQ ID NO:149; CDR2 od SEQ ID NO:150, i CDR3 od SEQ ID NO:151; ili j) varijabilno područje jakog lanca CDR1 od SEQ ID NO:164; CDR2 od SEQ ID NO:165; CDR3 od SEQ ID NO:166; varijabilno područje slabog lanca CDR1 od SEQ ID NO:167; CDR2 od SEQ ID NO:168, i CDR3 od SEQ ID NO:169; ili k) varijabilno područje jakog lanca CDR1 od SEQ ID NO:182; CDR2 od SEQ ID NO:183; CDR3 od SEQ ID NO:184; varijabilno područje slabog lanca CDR1 od SEQ ID NO:185; CDR2 od SEQ ID NO:186, i CDR3 od SEQ ID NO:187; ili l) varijabilno područje jakog lanca CDR1 od SEQ ID NO:200; CDR2 od SEQ ID NO:201; CDR3 od SEQ ID NO:202; varijabilno područje slabog lanca CDR1 od SEQ ID NO:203; CDR2 od SEQ ID NO:204, i CDR3 od SEQ ID NO:205; ili m) varijabilno područje jakog lanca CDR1 od SEQ ID NO:218; CDR2 od SEQ ID NO:219; CDR3 od SEQ ID NO:220; varijabilno područje slabog lanca CDR1 od SEQ ID NO:221; CDR2 od SEQ ID NO:222, i CDR3 od SEQ ID NO:223; ili n) varijabilno područje jakog lanca CDR1 od SEQ ID NO:236; CDR2 od SEQ ID NO:237; CDR3 od SEQ ID NO:238; varijabilno područje slabog lanca CDR1 od SEQ ID NO:239; CDR2 od SEQ ID NO:240, i CDR3 od SEQ ID NO:241; ili o) varijabilno područje jakog lanca CDR1 od SEQ ID NO:254; CDR2 od SEQ ID NO:255; CDR3 od SEQ ID NO:256; varijabilno područje slabog lanca CDR1 od SEQ ID NO:257; CDR2 od SEQ ID NO:258, i CDR3 od SEQ ID NO:259; ili p) varijabilno područje jakog lanca CDR1 od SEQ ID NO:272; CDR2 od SEQ ID NO:273; CDR3 od SEQ ID NO:274; varijabilno područje slabog lanca CDR1 od SEQ ID NO:275; CDR2 od SEQ ID NO:276, i CDR3 od SEQ ID NO:277; ili q) varijabilno područje jakog lanca CDR1 od SEQ ID NO:290; CDR2 od SEQ ID NO:291; CDR3 od SEQ ID NO:292; varijabilno područje slabog lanca CDR1 od SEQ ID NO:293; CDR2 od SEQ ID NO:294, i CDR3 od SEQ ID NO:295; ili r) varijabilno područje jakog lanca CDR1 od SEQ ID NO:308; CDR2 od SEQ ID NO:309; CDR3 od SEQ ID NO:310; varijabilno područje slabog lanca CDR1 od SEQ ID NO:311; CDR2 od SEQ ID NO:312, i CDR3 od SEQ ID NO:313; ili s) varijabilno područje jakog lanca CDR1 od SEQ ID NO:326; CDR2 od SEQ ID NO:327; CDR3 od SEQ ID NO:328; varijabilno područje slabog lanca CDR1 od SEQ ID NO:329; CDR2 od SEQ ID NO:330, i CDR3 od SEQ ID NO:331; ili t) varijabilno područje jakog lanca CDR1 od SEQ ID NO:344; CDR2 od SEQ ID NO:345; CDR3 od SEQ ID NO:346; varijabilno područje slabog lanca CDR1 od SEQ ID NO:347; CDR2 od SEQ ID NO:348, i CDR3 od SEQ ID NO:349; ili u) varijabilno područje jakog lanca CDR1 od SEQ ID NO:362; CDR2 od SEQ ID NO:363; CDR3 od SEQ ID NO:364; varijabilno područje slabog lanca CDR1 od SEQ ID NO:365; CDR2 od SEQ ID NO:366, i CDR3 od SEQ ID NO:367.
27. Fragment protutijela prema bilo kojem od prethodnih zahtjeva, naznačen time, da je odabran iz skupine koju čine: Fab, F(ab2)', F(ab)2', scFv, VHH, VH, VL, dAbs.
28. Farmaceutski sastav, naznačen time, da obuhvaća protutijelo ili njegov fragment odabran prema bilo kojem od prethodnih zahtjeva, i farmaceutski prihvatljiv nosač.
29. Farmaceutski sastav prema zahtjevu 28, naznačen time, da nadalje obuhvaća dodatno terapeutsko sredstvo.
30. Farmaceutski sastav prema zahtjevu 29, naznačen time, da je dodatno terapeutsko sredstvo odabrano iz skupine koju čine: HER1-inhibitor, HER2-inhibitor, HER3-inhibitor, HER4-inhibitor, mTOR-inhibitor, i inhibitor PI3-kinaze.
31. Farmaceutski sastav prema zahtjevu 30, naznačen time, da: a) kada je dodatno terapeutsko sredstvo jedan HER1-inhibitor, tada se HER1-inhibitor odabire iz skupine koju čine: Matuzumab (EMD72000), Erbitux®/Cetuximab, Vectibix®/Panitumumab, mAb 806, Nimotuzumab, Iressa®/Gefitinib, CI-1033 (PD183805), Lapatinib (GW-572016), Tykerb®/Lapatinib Ditosylate, Tarceva®/Erlotinib HCL (OSI-774), PKI-166, i Tovok®; HER2-inhibitor se odabire iz skupine koju čine: Pertuzumab, Trastuzumab, MM-111, neratinib, lapatinib ili lapatinib ditosylate/Tykerb®; HER3-inhibitor se odabire iz skupine koju čine: MM-121, MM-111, IB4C3, 2DID12 (U3 Pharma AG), AMG888 (Amgen), AV-203 (Aveo), MEHD7945A (Genentech) i male molekule koje inhibiraju HER3; i HER4-inhibitor; b) kada je dodatno terapeutsko sredstvo jedan mTOR-inhibitor, tada se mTOR-inhibitor odabire iz skupine koju čine: Temsirolimus/Torisel®, ridaforolimus/Deforolimus, AP23573, MK8669, everolimus/Affinitor®; c) kada je dodatno terapeutsko sredstvo jedan inhibitor PI3-kinaze, tada se inhibitor PI3-kinaze odabire iz skupine koju čine: GDC 0941, BEZ235, BMK120 i BYL719.
32. Protutijelo ili njegov fragment prema bilo kojem od zahtjeva 1 do 27, ili sastav prema bilo kojem od zahtjeva 28 do 31, naznačen/o time, da se upotrebljava kao lijek.
33. Protutijelo ili njegov fragment prema bilo kojem od zahtjeva 1 do 27, ili sastav prema bilo kojem od zahtjeva 28 do 31, naznačen/o time, da se upotrebljava u liječenju raka koji izražava HER3.
34. Protutijelo ili njegov fragment prema bilo kojem od zahtjeva 1 do 27, ili sastav prema bilo kojem od zahtjeva 28 do 31, za uporabu u liječenju raka prema zahtjevu 33, naznačen/o time, da se rak posreduje preko
35. HER3-signalnog puta.
36. Protutijelo ili njegov fragment prema bilo kojem od zahtjeva 1 do 27, ili sastav prema bilo kojem od zahtjeva 28 do 31, za uporabu u liječenju raka prema zahtjevu 33, naznačen/o time, da je rak odabran iz skupine koja se sastoji od sljedećih: rak dojke, kolorektalni rak, rak pluća, višestruki mijelom, rak jajnika, rak jetre, rak želudca, rak gušterače, rak prostate, akutna mijeloidna leukemija, kronična mijeloidna leukemija, osteosarkom, karcinom pločastih stanica, tumori perifernih obloženih živaca, švanom, rak glave i vrata, rak mjehura, rak jednjaka, glioblastom, sarkom mekog tkiva -„clear cell sarkom“, maligni mezoteliom, neurofibromatoza, rak bubrega i melanom.
HRP20170462TT 2010-08-20 2017-03-21 Protutijela za epidermalni receptor 3 faktora rasta (her3) HRP20170462T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37540810P 2010-08-20 2010-08-20
EP11746252.3A EP2606070B1 (en) 2010-08-20 2011-08-22 Antibodies for epidermal growth factor receptor 3 (her3)
PCT/EP2011/064407 WO2012022814A1 (en) 2010-08-20 2011-08-22 Antibodies for epidermal growth factor receptor 3 (her3)

Publications (1)

Publication Number Publication Date
HRP20170462T1 true HRP20170462T1 (hr) 2017-05-19

Family

ID=44630597

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20170462TT HRP20170462T1 (hr) 2010-08-20 2017-03-21 Protutijela za epidermalni receptor 3 faktora rasta (her3)

Country Status (37)

Country Link
US (3) US8735551B2 (hr)
EP (1) EP2606070B1 (hr)
JP (4) JP6057896B2 (hr)
KR (1) KR102027011B1 (hr)
CN (2) CN105037552B (hr)
AU (1) AU2011290672B2 (hr)
BR (1) BR112013004012B1 (hr)
CA (1) CA2806637C (hr)
CL (2) CL2013000459A1 (hr)
CO (1) CO6680688A2 (hr)
CR (1) CR20130071A (hr)
CU (1) CU24094B1 (hr)
CY (1) CY1118761T1 (hr)
DK (1) DK2606070T3 (hr)
DO (1) DOP2013000044A (hr)
EA (1) EA036314B1 (hr)
ES (1) ES2620255T3 (hr)
GE (1) GEP201706605B (hr)
GT (1) GT201300046A (hr)
HR (1) HRP20170462T1 (hr)
HU (1) HUE031855T2 (hr)
IL (2) IL226712B (hr)
LT (1) LT2606070T (hr)
MA (1) MA34524B1 (hr)
ME (1) ME02637B (hr)
MX (1) MX2013002046A (hr)
MY (1) MY162825A (hr)
NI (1) NI201300023A (hr)
NZ (1) NZ607337A (hr)
PE (1) PE20140230A1 (hr)
PL (1) PL2606070T3 (hr)
PT (1) PT2606070T (hr)
RS (1) RS55930B1 (hr)
SG (1) SG187908A1 (hr)
SI (1) SI2606070T1 (hr)
UA (1) UA114883C2 (hr)
WO (1) WO2012022814A1 (hr)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY161909A (en) 2009-12-22 2017-05-15 Roche Glycart Ag Anti-her3 antibodies and uses thereof
PT2606070T (pt) * 2010-08-20 2017-03-31 Novartis Ag Anticorpos para o recetor 3 do fator de crescimento epidérmico (her3)
EP2635604B1 (en) 2010-11-01 2016-11-30 Symphogen A/S Pan-her antibody composition
ITRM20100577A1 (it) * 2010-11-02 2012-05-03 Takis Srl Immunoterapia contro il recettore erbb-3
SI2699602T1 (sl) 2011-04-19 2017-06-30 Merrimack Pharmaceuticals, Inc. Bispecifična protitelesa anti-igf-1r in anti-erbb3
JPWO2012176779A1 (ja) * 2011-06-20 2015-02-23 協和発酵キリン株式会社 抗ｅｒｂＢ３抗体
US9273143B2 (en) 2011-09-30 2016-03-01 Regeneron Pharmaceuticals, Inc. Methods and compositions comprising a combination of an anti-ErbB3 antibody and an anti-EGFR antibody
EP2760893B1 (en) 2011-09-30 2018-09-12 Regeneron Pharmaceuticals, Inc. Anti-erbb3 antibodies and uses thereof
GB2504139B (en) * 2012-07-20 2014-12-31 Argen X Bv Antibodies to highly conserved targets produced by the immunisation of Camelidae species
JP6149042B2 (ja) * 2011-11-09 2017-06-14 ザ ユーエービー リサーチ ファンデーション Ｈｅｒ３抗体およびその使用
RU2620068C2 (ru) * 2011-11-23 2017-05-22 МЕДИММЬЮН, ЭлЭлСи Связывающие молекулы, специфичные по отношению к her3, и их применения
KR20140103135A (ko) * 2011-12-05 2014-08-25 노파르티스 아게 Her3의 도메인 ii에 대해 지시된 표피 성장 인자 수용체 3 (her3)에 대한 항체
KR102083957B1 (ko) * 2011-12-05 2020-03-04 노파르티스 아게 표피 성장 인자 수용체 3 (her3)에 대한 항체
WO2013124297A1 (en) * 2012-02-22 2013-08-29 U3 Pharma Gmbh Combination of hb-egf binding protein and egfr inhibitor
TR201816416T4 (tr) 2012-08-21 2018-11-21 Janssen Pharmaceutica Nv Risperidona yönelik antikorlar ve bunların kullanımı.
CA2928539A1 (en) * 2012-10-25 2014-05-01 Sorrento Therapeutics, Inc. Antigen binding proteins that bind erbb3
KR20150063565A (ko) * 2012-11-08 2015-06-09 에프. 호프만-라 로슈 아게 Her3의 베타-헤어핀 및 her4의 베타-헤어핀에 결합하는 항-her3/her4 항원 결합 단백질
WO2014072306A1 (en) 2012-11-08 2014-05-15 F. Hoffmann-La Roche Ag Her3 antigen binding proteins binding to the beta-hairpin of her3
CN102993305B (zh) * 2012-11-16 2015-05-13 上海赛伦生物技术有限公司 人源抗人表皮生长因子受体抗体及其编码基因与应用
AR094403A1 (es) 2013-01-11 2015-07-29 Hoffmann La Roche Terapia de combinación de anticuerpos anti-her3
WO2015042275A1 (en) * 2013-09-18 2015-03-26 Sloan-Kettering Institute For Cancer Research Methods and compositions for imaging disorders using polyspecific agents
WO2015048008A2 (en) 2013-09-24 2015-04-02 Medimmune, Llc Binding molecules specific for her3 and uses thereof
US10570204B2 (en) 2013-09-26 2020-02-25 The Medical College Of Wisconsin, Inc. Methods for treating hematologic cancers
US10519247B2 (en) * 2013-11-01 2019-12-31 Board Of Regents,The University Of Texas System Targeting HER2 and HER3 with bispecific antibodies in cancerous cells
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
WO2015130172A1 (en) 2014-02-28 2015-09-03 Merus B.V. Antibodies that bind egfr and erbb3
US11279770B2 (en) 2014-02-28 2022-03-22 Merus N.V. Antibody that binds ErbB-2 and ErbB-3
EP3116909B1 (en) 2014-03-14 2019-11-13 Novartis Ag Antibody molecules to lag-3 and uses thereof
US10745490B2 (en) 2014-04-11 2020-08-18 Celldex Therapeutics, Inc. Anti-ErbB antibodies and methods of use thereof
FR3020063A1 (fr) 2014-04-16 2015-10-23 Gamamabs Pharma Anticorps humain anti-her4
WO2015173250A1 (en) * 2014-05-14 2015-11-19 F. Hoffmann-La Roche Ag Anti-her3 antibodies binding to the beta-hairpin of her3
MX2016014862A (es) 2014-05-14 2017-02-27 Hoffmann La Roche Her3 / her2 anticuerpos biespecificos que se unen a la horquilla beta de her3 y al dominio ii de her2.
US20170291956A1 (en) * 2014-07-16 2017-10-12 David Livingston HER3 Inhibition in Low-grade Serous Ovarian Cancers
CN110642952B (zh) * 2014-08-14 2021-05-25 上海生物制品研究所有限责任公司 抗her3抗体、其制法及其应用
EP3925622A1 (en) 2014-09-13 2021-12-22 Novartis AG Combination therapies
CA2963281A1 (en) * 2014-10-03 2016-04-07 Novartis Ag Combination therapies
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
EP4245376A3 (en) 2014-10-14 2023-12-13 Novartis AG Antibody molecules to pd-l1 and uses thereof
WO2016092508A1 (en) 2014-12-12 2016-06-16 Massachusetts General Hospital Treatment of breast cancer brain metastases
JO3746B1 (ar) 2015-03-10 2021-01-31 Aduro Biotech Inc تركيبات وطرق لتنشيط الإشارات المعتمدة على "منبه أو تحفيز جين انترفيرون"
CA2991799A1 (en) * 2015-07-15 2017-01-19 Zymeworks Inc. Drug-conjugated bi-specific antigen-binding constructs
TW201716439A (zh) 2015-07-20 2017-05-16 美國禮來大藥廠 Ｈｅｒ３抗體
EP3328418A1 (en) 2015-07-29 2018-06-06 Novartis AG Combination therapies comprising antibody molecules to pd-1
LT3317301T (lt) 2015-07-29 2021-07-26 Novartis Ag Kombinuotos terapijos, apimančios antikūno molekules prieš lag-3
US20180207273A1 (en) 2015-07-29 2018-07-26 Novartis Ag Combination therapies comprising antibody molecules to tim-3
EP3334762A1 (en) * 2015-08-14 2018-06-20 Allergan, Inc. Heavy chain only antibodies to pdgf
CN108602888B (zh) 2015-10-23 2022-10-04 美勒斯公司 抑制癌症生长的结合分子
MA43186B1 (fr) 2015-11-03 2022-03-31 Janssen Biotech Inc Anticorps se liant spécifiquement à pd-1 et leurs utilisations
CA2949032A1 (en) 2015-11-30 2017-05-30 Pfizer Inc. Site specific her2 antibody drug conjugates
JP6629581B2 (ja) * 2015-11-30 2020-01-15 サントリーホールディングス株式会社 ヒドロキシチロソール含有茶飲料
KR101746152B1 (ko) * 2015-12-07 2017-06-13 주식회사 이수앱지스 ＥｒｂＢ3에 특이적으로 결합하는 항체 및 그의 용도
MA43416A (fr) 2015-12-11 2018-10-17 Regeneron Pharma Méthodes pour ralentir ou empêcher la croissance de tumeurs résistantes au blocage de l'egfr et/ou d'erbb3
MX2018007423A (es) 2015-12-17 2018-11-09 Novartis Ag Moleculas de anticuerpo que se unen a pd-1 y usos de las mismas.
MX2018011054A (es) 2016-03-15 2019-01-21 Merrimack Pharmaceuticals Inc Metodos para tratar cancer de mama er+, her2-, hrg+ usando terapias de combinacion que comprenden un anticuerpo anti-erbb3.
EP3507367A4 (en) 2016-07-05 2020-03-25 Aduro BioTech, Inc. CYCLIC DINUCLEOTID COMPOUNDS WITH INCLUDED NUCLEIC ACIDS AND USES THEREOF
TW201834696A (zh) 2017-02-28 2018-10-01 學校法人近畿大學 藉由投予抗her3抗體－藥物複合體之egfr－tki抗性之非小細胞肺癌的治療方法
CA3058342A1 (en) 2017-03-31 2018-10-04 Merus N.V. Erbb-2 targeting agent and a bispecific antibody with antigen-binding sites that bind an epitope on an extracellular part of erb-2 and erbb-3, for treatment of an individual with an erbb-2, erbb-2/erbb-3 positive tumour
AU2018246873B2 (en) 2017-03-31 2021-05-06 Merus N.V. ErbB-2 and ErbB3 binding bispecific antibodies for use in the treatment f cells that have an NRG1 fusion gene
UY37695A (es) 2017-04-28 2018-11-30 Novartis Ag Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
EP3642240A1 (en) 2017-06-22 2020-04-29 Novartis AG Antibody molecules to cd73 and uses thereof
SG11202001050PA (en) 2017-08-09 2020-03-30 Merus Nv Antibodies that bind egfr and cmet
KR20200058411A (ko) 2017-08-30 2020-05-27 베이징 슈안이 파마사이언시스 컴퍼니, 리미티드 인터페론 유전자 조절인자의 자극제로서의 환식 다이-뉴클레오타이드
JP7378394B2 (ja) 2017-11-03 2023-11-13 オーリジーン オンコロジー リミテッド Ｔｉｍ－３およびｐｄ－１経路の二重阻害剤
EP3706798A1 (en) 2017-11-06 2020-09-16 Aurigene Discovery Technologies Limited Conjoint therapies for immunomodulation
WO2019185164A1 (en) * 2018-03-29 2019-10-03 Hummingbird Bioscience Holdings Pte. Ltd. Her3 antigen-binding molecules
TW202015726A (zh) 2018-05-30 2020-05-01 瑞士商諾華公司 Ｅｎｔｐｄ２抗體、組合療法、及使用該等抗體和組合療法之方法
KR20210062005A (ko) 2018-09-20 2021-05-28 다이이찌 산쿄 가부시키가이샤 항 her3 항체-약물 콘쥬게이트 투여에 의한 her3 변이암의 치료
CN110760003A (zh) * 2019-09-10 2020-02-07 广东药科大学 一种抗her3单链抗体的制备方法
CN114502590A (zh) 2019-09-18 2022-05-13 诺华股份有限公司 Entpd2抗体、组合疗法、以及使用这些抗体和组合疗法的方法
CN113788895B (zh) * 2021-10-14 2023-09-15 陕西健吉跃生物科技有限公司 一种兔多克隆抗体及其制备方法和应用

Family Cites Families (185)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
ATE37983T1 (de) 1982-04-22 1988-11-15 Ici Plc Mittel mit verzoegerter freigabe.
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
CA1247080A (en) 1983-03-08 1988-12-20 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
EP0154316B1 (en) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
US5128326A (en) 1984-12-06 1992-07-07 Biomatrix, Inc. Drug delivery systems based on hyaluronans derivatives thereof and their salts and methods of producing same
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4881175A (en) 1986-09-02 1989-11-14 Genex Corporation Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
US5013653A (en) 1987-03-20 1991-05-07 Creative Biomolecules, Inc. Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage
DE3856559T2 (de) 1987-05-21 2004-04-29 Micromet Ag Multifunktionelle Proteine mit vorbestimmter Zielsetzung
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US4880078A (en) 1987-06-29 1989-11-14 Honda Giken Kogyo Kabushiki Kaisha Exhaust muffler
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
US5336603A (en) 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
US5476996A (en) 1988-06-14 1995-12-19 Lidak Pharmaceuticals Human immune system in non-human animal
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
KR900005995A (ko) 1988-10-31 1990-05-07 우메모또 요시마사 변형 인터류킨-2 및 그의 제조방법
ES2052027T5 (es) 1988-11-11 2005-04-16 Medical Research Council Clonacion de secuencias de dominio variable de inmunoglobulina.
ATE135370T1 (de) 1988-12-22 1996-03-15 Kirin Amgen Inc Chemisch modifizierte granulocytenkolonie erregender faktor
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
ATE92107T1 (de) 1989-04-29 1993-08-15 Delta Biotechnology Ltd N-terminale fragmente von menschliches serumalbumin enthaltenden fusionsproteinen.
US6291158B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertoire
US5112946A (en) 1989-07-06 1992-05-12 Repligen Corporation Modified pf4 compositions and methods of use
FR2650598B1 (fr) 1989-08-03 1994-06-03 Rhone Poulenc Sante Derives de l'albumine a fonction therapeutique
WO1991005548A1 (en) 1989-10-10 1991-05-02 Pitman-Moore, Inc. Sustained release composition for macromolecular proteins
WO1991006570A1 (en) 1989-10-25 1991-05-16 The University Of Melbourne HYBRID Fc RECEPTOR MOLECULES
CA2071867A1 (en) 1989-11-06 1991-05-07 Edith Mathiowitz Method for producing protein microspheres
US5183884A (en) 1989-12-01 1993-02-02 United States Of America Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
AU633698B2 (en) 1990-01-12 1993-02-04 Amgen Fremont Inc. Generation of xenogeneic antibodies
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5349053A (en) 1990-06-01 1994-09-20 Protein Design Labs, Inc. Chimeric ligand/immunoglobulin molecules and their uses
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1992003918A1 (en) 1990-08-29 1992-03-19 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
JP3242916B2 (ja) 1990-12-14 2001-12-25 セル ジェネシス，インコーポレイティド レセプター関連シグナル変換系のためのキメラ鎖
AU666852B2 (en) 1991-05-01 1996-02-29 Henry M. Jackson Foundation For The Advancement Of Military Medicine A method for treating infectious respiratory diseases
ATE275198T1 (de) 1991-12-02 2004-09-15 Medical Res Council Herstellung von antikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken.
EP0616640B1 (en) 1991-12-02 2004-09-01 Medical Research Council Production of anti-self antibodies from antibody segment repertoires and displayed on phage
EP0746609A4 (en) 1991-12-17 1997-12-17 Genpharm Int NON-HUMAN TRANSGENIC ANIMALS CAPABLE OF PRODUCING HETEROLOGOUS ANTIBODIES
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
FR2686901A1 (fr) 1992-01-31 1993-08-06 Rhone Poulenc Rorer Sa Nouveaux polypeptides antithrombotiques, leur preparation et compositions pharmaceutiques les contenant.
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5912015A (en) 1992-03-12 1999-06-15 Alkermes Controlled Therapeutics, Inc. Modulated release from biocompatible polymers
US5447851B1 (en) 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
AU4116793A (en) 1992-04-24 1993-11-29 Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
US6765087B1 (en) 1992-08-21 2004-07-20 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
DK0656946T4 (da) 1992-08-21 2010-07-26 Univ Bruxelles Immunoglobuliner uden lette kæder
US5958708A (en) 1992-09-25 1999-09-28 Novartis Corporation Reshaped monoclonal antibodies against an immunoglobulin isotype
CA2103323A1 (en) 1992-11-24 1994-05-25 Gregory D. Plowman Her4 human receptor tyrosine kinase
US5934272A (en) 1993-01-29 1999-08-10 Aradigm Corporation Device and method of creating aerosolized mist of respiratory drug
EP0754225A4 (en) 1993-04-26 2001-01-31 Genpharm Int HETEROLOGIC ANTIBODY-PRODUCING TRANSGENIC NON-HUMAN ANIMALS
AU6796094A (en) 1993-04-29 1994-11-21 Raymond Hamers Production of antibodies or (functionalized) fragments thereof derived from heavy chain immunoglobulins of (camelidae)
JPH08511420A (ja) 1993-06-16 1996-12-03 セルテック・セラピューテイクス・リミテッド 抗 体
SE9400088D0 (sv) 1994-01-14 1994-01-14 Kabi Pharmacia Ab Bacterial receptor structures
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US5834252A (en) 1995-04-18 1998-11-10 Glaxo Group Limited End-complementary polymerase reaction
US5837458A (en) 1994-02-17 1998-11-17 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
CN1117155C (zh) 1994-07-29 2003-08-06 史密丝克莱恩比彻姆有限公司 新型化合物
US6132764A (en) 1994-08-05 2000-10-17 Targesome, Inc. Targeted polymerized liposome diagnostic and treatment agents
WO1996020698A2 (en) 1995-01-05 1996-07-11 The Board Of Regents Acting For And On Behalf Of The University Of Michigan Surface-modified nanoparticles and method of making and using same
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6019968A (en) 1995-04-14 2000-02-01 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
CA2230494A1 (en) 1995-08-31 1997-03-06 Alkermes Controlled Therapeutics Inc. Composition for sustained release of an agent
AU2063197A (en) 1996-03-04 1997-09-22 Massachusetts Institute Of Technology Materials and methods for enhancing cellular internalization
WO1997034631A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
US5985309A (en) 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
US6056973A (en) 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
WO1998023289A1 (en) 1996-11-27 1998-06-04 The General Hospital Corporation MODULATION OF IgG BINDING TO FcRn
CA2277801C (en) 1997-01-16 2002-10-15 Massachusetts Institute Of Technology Preparation of particles for inhalation
US6136558A (en) 1997-02-10 2000-10-24 Genentech, Inc. Heregulin variants
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
ES2258817T3 (es) 1997-05-21 2006-09-01 Biovation Limited Metodo para la produccion de proteinas no inmunogenas.
WO1998056906A1 (en) 1997-06-11 1998-12-17 Thoegersen Hans Christian Trimerising module
JP3614866B2 (ja) 1997-06-12 2005-01-26 リサーチ コーポレイション テクノロジーズ，インコーポレイティド 人工抗体ポリペプチド
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
WO1999019488A1 (en) 1997-10-15 1999-04-22 Children's Medical Center Corporation Novel human egf receptors and use thereof
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
SE512663C2 (sv) 1997-10-23 2000-04-17 Biogram Ab Inkapslingsförfarande för aktiv substans i en bionedbrytbar polymer
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
PT1071700E (pt) 1998-04-20 2010-04-23 Glycart Biotechnology Ag Modificação por glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos
WO1999066903A2 (en) 1998-06-24 1999-12-29 Advanced Inhalation Research, Inc. Large porous particles emitted from an inhaler
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
KR100940380B1 (ko) 1999-01-15 2010-02-02 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
ES2571230T3 (es) 1999-04-09 2016-05-24 Kyowa Hakko Kirin Co Ltd Procedimiento para controlar la actividad de una molécula inmunofuncional
DE19932688B4 (de) 1999-07-13 2009-10-08 Scil Proteins Gmbh Design von Beta-Faltblatt-Proteinen des gamma-II-kristallins antikörperähnlichen
CA2347973C (en) 1999-07-20 2010-06-22 Morphosys Ag Novel methods for displaying (poly)peptides/proteins on bacteriophage particles via disulfide bonds
MXPA02001911A (es) 1999-08-24 2003-07-21 Medarex Inc Anticuerpos ctla-4 humanos y sus usos.
EP2267026A1 (en) 2000-04-12 2010-12-29 Human Genome Sciences, Inc. Albumin fusion proteins
US7943129B2 (en) 2000-05-26 2011-05-17 National Research Council Of Canada Single-domain brain-targeting antibody fragments derived from llama antibodies
ES2405944T3 (es) 2000-11-30 2013-06-04 Medarex, Inc. Ácidos nucleicos que codifican las secuencias de inmunoglobulina humana reorganizadas a partir de ratones transcromoscómicos transgénicos zadas
CZ307637B6 (cs) 2001-02-19 2019-01-23 Novartis Ag 40-O-(2-Hydroxyethyl)rapamycin jako jediná účinná látka při léčení
US20050053973A1 (en) 2001-04-26 2005-03-10 Avidia Research Institute Novel proteins with targeted binding
US20050048512A1 (en) 2001-04-26 2005-03-03 Avidia Research Institute Combinatorial libraries of monomer domains
US20040175756A1 (en) 2001-04-26 2004-09-09 Avidia Research Institute Methods for using combinatorial libraries of monomer domains
WO2002092780A2 (en) 2001-05-17 2002-11-21 Diversa Corporation Novel antigen binding molecules for therapeutic, diagnostic, prophylactic, enzymatic, industrial, and agricultural applications, and methods for generating and screening thereof
EP1399484B1 (en) 2001-06-28 2010-08-11 Domantis Limited Dual-specific ligand and its use
ITMI20011483A1 (it) 2001-07-11 2003-01-11 Res & Innovation Soc Coop A R Uso di composti come antagonisti funzionali ai recettori centrali deicannabinoidi
US7125680B2 (en) * 2001-07-27 2006-10-24 The Regents Of The University Of California Methods and materials for characterizing and modulating interaction between heregulin and HER3
EP1283053A1 (en) 2001-08-09 2003-02-12 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibitors of HER3 activity
AU2002337935B2 (en) 2001-10-25 2008-05-01 Genentech, Inc. Glycoprotein compositions
DE60226641D1 (de) 2001-12-03 2008-06-26 Amgen Fremont Inc Antikörperkategorisierung auf der grundlage von bindungseigenschaften
EP1478648B1 (en) 2002-02-01 2014-04-30 ARIAD Pharmaceuticals, Inc. Phosphorus-containing compounds and uses thereof
US7335478B2 (en) 2002-04-18 2008-02-26 Kalobios Pharmaceuticals, Inc. Reactivation-based molecular interaction sensors
US20030157579A1 (en) 2002-02-14 2003-08-21 Kalobios, Inc. Molecular sensors activated by disinhibition
AU2003217912A1 (en) 2002-03-01 2003-09-16 Xencor Antibody optimization
ATE328906T1 (de) 2002-06-28 2006-06-15 Domantis Ltd Dual-specifische liganden mit erhöhter halbwertszeit
WO2004041865A2 (en) 2002-11-08 2004-05-21 Ablynx N.V. Stabilized single domain antibodies
EP1578801A2 (en) 2002-12-27 2005-09-28 Domantis Limited Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand
US20050008625A1 (en) 2003-02-13 2005-01-13 Kalobios, Inc. Antibody affinity engineering by serial epitope-guided complementarity replacement
WO2004101790A1 (en) 2003-05-14 2004-11-25 Domantis Limited A process for recovering polypeptides that unfold reversibly from a polypeptide repertoire
DE10324447A1 (de) 2003-05-28 2004-12-30 Scil Proteins Gmbh Generierung künstlicher Bindungsproteine auf der Grundlage von Ubiquitin
CA2529819A1 (en) 2003-06-30 2004-09-23 Domantis Limited Pegylated single domain antibodies
US7399865B2 (en) 2003-09-15 2008-07-15 Wyeth Protein tyrosine kinase enzyme inhibitors
EP1761561B1 (en) 2004-01-20 2015-08-26 KaloBios Pharmaceuticals, Inc. Antibody specificity transfer using minimal essential binding determinants
US20060008844A1 (en) 2004-06-17 2006-01-12 Avidia Research Institute c-Met kinase binding proteins
WO2006079372A1 (en) 2005-01-31 2006-08-03 Ablynx N.V. Method for generating variable domain sequences of heavy chain antibodies
GB0503546D0 (en) * 2005-02-21 2005-03-30 Hellenic Pasteur Inst Antibody
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
EA200800766A1 (ru) 2005-09-07 2008-06-30 Лаборатуар Сероно С.А. Ингибиторы pi3k для лечения эндометриоза
JP2009506790A (ja) 2005-09-07 2009-02-19 メディミューン，エルエルシー 毒素とコンジュゲートしたｅｐｈ受容体抗体
EP1973576B1 (en) 2005-11-28 2019-05-15 Genmab A/S Recombinant monovalent antibodies and methods for production thereof
AR056857A1 (es) * 2005-12-30 2007-10-24 U3 Pharma Ag Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos
SG172692A1 (en) 2006-06-12 2011-07-28 Symphogen As Pan-cell surface receptor- specific therapeutics
CN101522717A (zh) * 2006-08-04 2009-09-02 阿斯利康(瑞典)有限公司 针对ErbB2的人抗体
WO2008022746A1 (en) * 2006-08-21 2008-02-28 F. Hoffmann-La Roche Ag Tumor therapy with an anti-vegf antibody
US7825127B2 (en) 2006-12-28 2010-11-02 Takeda Pharmaceutical Company, Limited Method for treating cancer
EP3248617A3 (en) 2007-02-16 2018-02-21 Merrimack Pharmaceuticals, Inc. Antibodies against erbb3 and uses thereof
MX2009008981A (es) 2007-03-02 2009-09-02 Genentech Inc Prediccion de respuesta a un inhibidor her.
US20080245375A1 (en) 2007-04-05 2008-10-09 Medtronic Vascular, Inc. Benign Prostatic Hyperplasia Treatments
US8247397B2 (en) 2007-09-12 2012-08-21 Genentech, Inc. Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use
WO2009052184A2 (en) 2007-10-16 2009-04-23 Receptor Biologix, Inc. Compositions comprising optimized her1 and her3 multimers and methods of use thereof
US8354528B2 (en) 2007-10-25 2013-01-15 Genentech, Inc. Process for making thienopyrimidine compounds
UY31800A (es) 2008-05-05 2009-11-10 Smithkline Beckman Corp Metodo de tratamiento de cancer usando un inhibidor de cmet y axl y un inhibidor de erbb
WO2010127181A1 (en) 2009-04-29 2010-11-04 Trellis Bioscience, Inc. Improved antibodies immunoreactive with heregulin-coupled her3
KR20120059568A (ko) 2009-08-21 2012-06-08 메리맥 파마슈티컬즈, 인크. Ｅｒｂｂ３의 엑토도메인에 대한 항체 및 이의 용도
US8654108B2 (en) 2009-09-25 2014-02-18 Sharp Kabushiki Kaisha Liquid crystal display device
JP2013507926A (ja) 2009-10-14 2013-03-07 メリマック ファーマシューティカルズ インコーポレーティッド ＩＧＦ−１Ｒ及びＥｒｂＢ３シグナル伝達を標的とする二重特異的結合剤及びその使用
TWI630916B (zh) 2009-11-13 2018-08-01 第一三共歐洲公司 供治療或預防人表皮生長因子受體－３（ｈｅｒ－３）相關疾病之藥料和方法
MY161909A (en) 2009-12-22 2017-05-15 Roche Glycart Ag Anti-her3 antibodies and uses thereof
EP2536748B1 (en) 2010-02-18 2014-08-20 Genentech, Inc. Neuregulin antagonists and use thereof in treating cancer
SG183532A1 (en) 2010-03-11 2012-09-27 Merrimack Pharmaceuticals Inc Use of erbb3 inhibitors in the treatment of triple negative and basal-like breast cancers
ES2566602T3 (es) 2010-04-09 2016-04-14 Aveo Pharmaceuticals, Inc. Anticuerpos anti-ErbB3
CA2799217A1 (en) 2010-05-13 2011-11-17 Fox Chase Cancer Center Recombinantly produced antibodies targeting erbb signaling molecules and methods of use thereof for the diagnosis and treatment of disease
WO2011144749A1 (en) 2010-05-20 2011-11-24 Ablynx Nv Biological materials related to her3
UY33492A (es) 2010-07-09 2012-01-31 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
WO2012019024A2 (en) 2010-08-04 2012-02-09 Immunogen, Inc. Her3-binding molecules and immunoconjugates thereof
WO2012018404A2 (en) 2010-08-06 2012-02-09 U3 Pharma Gmbh Use of her3 binding agents in prostate treatment
PT2606070T (pt) * 2010-08-20 2017-03-31 Novartis Ag Anticorpos para o recetor 3 do fator de crescimento epidérmico (her3)
TW201302793A (zh) 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
US9155802B2 (en) 2010-11-01 2015-10-13 Symphogen A/S Pan-HER antibody composition
ITRM20100577A1 (it) 2010-11-02 2012-05-03 Takis Srl Immunoterapia contro il recettore erbb-3
US20120263722A1 (en) 2010-11-04 2012-10-18 Abbott Laboratories Dual Variable Domain Immunoglobulins and Uses Thereof
DK2707391T3 (en) 2011-05-13 2018-02-05 Gamamabs Pharma ANTIBODIES AGAINST HER3
CA2842860A1 (en) 2011-07-28 2013-01-31 Sea Lane Biotechnologies, Llc Sur-binding proteins
KR20140103135A (ko) 2011-12-05 2014-08-25 노파르티스 아게 Her3의 도메인 ii에 대해 지시된 표피 성장 인자 수용체 3 (her3)에 대한 항체
KR102083957B1 (ko) 2011-12-05 2020-03-04 노파르티스 아게 표피 성장 인자 수용체 3 (her3)에 대한 항체

Also Published As

Publication number Publication date
LT2606070T (lt) 2017-04-10
GT201300046A (es) 2015-06-02
WO2012022814A1 (en) 2012-02-23
JP6770944B2 (ja) 2020-10-21
CR20130071A (es) 2013-03-13
CN103080134A (zh) 2013-05-01
RS55930B1 (sr) 2017-09-29
GEP201706605B (en) 2017-01-25
CL2014002750A1 (es) 2015-04-06
PL2606070T4 (pl) 2017-06-30
JP6057896B2 (ja) 2017-01-11
US20170166653A1 (en) 2017-06-15
JP2017019815A (ja) 2017-01-26
PE20140230A1 (es) 2014-02-26
US10077317B2 (en) 2018-09-18
IL261916A (en) 2018-10-31
US20190194347A1 (en) 2019-06-27
CN105037552A (zh) 2015-11-11
CN103080134B (zh) 2015-11-25
AU2011290672A1 (en) 2013-03-21
EA201300256A1 (ru) 2013-08-30
ES2620255T3 (es) 2017-06-28
JP6771002B2 (ja) 2020-10-21
PT2606070T (pt) 2017-03-31
HUE031855T2 (en) 2017-08-28
IL226712B (en) 2018-10-31
JP2013537546A (ja) 2013-10-03
EP2606070A1 (en) 2013-06-26
BR112013004012B1 (pt) 2021-03-23
CO6680688A2 (es) 2013-05-31
CU20130023A7 (es) 2013-05-31
DOP2013000044A (es) 2013-05-31
CA2806637C (en) 2020-08-25
NI201300023A (es) 2013-04-15
MX2013002046A (es) 2013-04-03
MA34524B1 (fr) 2013-09-02
JP2018090590A (ja) 2018-06-14
JP2019001791A (ja) 2019-01-10
JP6416161B2 (ja) 2018-10-31
CA2806637A1 (en) 2012-02-23
NZ607337A (en) 2015-06-26
KR102027011B1 (ko) 2019-09-30
CL2013000459A1 (es) 2014-01-31
SI2606070T1 (sl) 2017-04-26
BR112013004012A2 (pt) 2016-06-28
MY162825A (en) 2017-07-31
AU2011290672B2 (en) 2015-07-09
CY1118761T1 (el) 2017-07-12
PL2606070T3 (pl) 2017-06-30
US20120107306A1 (en) 2012-05-03
CU24094B1 (es) 2015-04-29
SG187908A1 (en) 2013-03-28
DK2606070T3 (en) 2017-03-27
CN105037552B (zh) 2019-03-29
UA114883C2 (uk) 2017-08-28
ME02637B (me) 2017-06-20
EP2606070B1 (en) 2016-12-21
EA036314B1 (ru) 2020-10-26
US8735551B2 (en) 2014-05-27
KR20130108304A (ko) 2013-10-02

Similar Documents

Publication Publication Date Title
HRP20170462T1 (hr) Protutijela za epidermalni receptor 3 faktora rasta (her3)
JP2013537546A5 (hr)
US20230242669A1 (en) Antibody that binds erbb-2 and erbb-3
Merchant et al. Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent
US11673952B2 (en) Antibodies specific to delta 1 chain of T cell receptor
US8552157B2 (en) c-Kit antibodies and uses thereof
RU2016144176A (ru) Биспецифические антитела к her2
RU2012151823A (ru) Антитела против рецептора эпидермального фактора роста (egfr) и их применение
US9994632B2 (en) Humanized or affinity-matured anti Ang-2 antibody and uses thereof
RU2011111746A (ru) Композиции рекомбинантных антител против рецептора эпидермального фактора роста
KR20140026336A (ko) 항―ｈｅｒ3 항체 및 조성물
AU2015264550B2 (en) Ang2 antibodies
US20240101675A1 (en) Dual binding antibodies, methods of producing dual binding antibodies, and uses thereof
KR20240021162A (ko) Alpha 5 베타 1 인테그린 결합제 및 이의 용도
RU2018113269A (ru) АНТИТЕЛО, СПЕЦИФИЧЕСКИ СВЯЗЫВАЮЩЕЕСЯ С ErbB3, И ЕГО ПРИМЕНЕНИЕ
CA3180665A1 (en) Binding molecules for the treatment of cancer
AU2013201446B2 (en) Biological materials related to c-Met
고봉국 Studies of synergistic antibody combination for treatment of patients with HER2-positive cancer
NZ724012B2 (en) Antibody that binds erbb-2 and erbb-3